HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

Marcie J Hursting Selected Research

Thrombocytopenia (Thrombopenia)

1/2011Etiology and assessment of hypercoagulability with lessons from heparin-induced thrombocytopenia.
9/2010Emergency department awareness of heparin-induced thrombocytopenia: how frequently is risk assessment documented in patients with thrombosis?
8/2010Heparin-platelet factor 4 antibodies in intensive care patients: an observational seroprevalence study.
1/2010Impact of renal function on argatroban therapy during percutaneous coronary intervention.
7/2009Dosing patterns and outcomes in African American, Asian, and Hispanic patients with heparin-induced thrombocytopenia treated with argatroban.
1/2009Reducing harm associated with anticoagulation: practical considerations of argatroban therapy in heparin-induced thrombocytopenia.
12/2008Risk factors for major bleeding in patients with heparin-induced thrombocytopenia treated with argatroban: a retrospective study.
9/2008Predictors of clinical outcome in patients with heparin-induced thrombocytopenia treated with direct thrombin inhibition.
9/2008Argatroban anticoagulation in intensive care patients: effects of heart failure and multiple organ system failure.
6/2008Effect of body mass index on Argatroban therapy during percutaneous coronary intervention.
For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!


Choose Username:
Email:
Password:
Verify Password:


Marcie J Hursting Research Topics

Disease

43Thrombocytopenia (Thrombopenia)
01/2011 - 03/2002
31Thrombosis (Thrombus)
09/2010 - 03/2002
17Hemorrhage
01/2009 - 07/2004
4Stroke (Strokes)
10/2006 - 04/2004
3Obesity
08/2012 - 06/2008
2Intracranial Hemorrhages (Intracranial Hemorrhage)
12/2008 - 04/2004
1Neoplasms (Cancer)
08/2012
1Thrombophilia
01/2011
1Shock
08/2010
1Wounds and Injuries (Trauma)
08/2010
1Heart Failure
09/2008
1Body Weight (Weight, Body)
06/2008
1Coronary Artery Disease (Coronary Atherosclerosis)
01/2008
1Chest Pain (Chest Pains)
03/2007
1Antiphospholipid Syndrome (Antiphospholipid Antibody Syndrome)
10/2006
1Necrosis
10/2006
1Venous Thromboembolism
09/2006
1Renal Insufficiency (Renal Failure)
10/2005
1Chronic Kidney Failure (Chronic Renal Failure)
12/2004

Drug/Important Bio-Agent (IBA)

43Heparin (Liquaemin)FDA LinkGeneric
01/2011 - 03/2002
37argatroban (MPQA)FDA Link
01/2010 - 03/2002
18ThrombinFDA Link
01/2010 - 08/2003
5AntibodiesIBA
08/2010 - 03/2002
3Platelet Factor 4IBA
08/2010 - 02/2007
3Glycoproteins (Glycoprotein)IBA
01/2009 - 05/2008
3Warfarin (Coumadin)FDA LinkGeneric
10/2006 - 06/2005
1HormonesIBA
08/2012
1CytokinesIBA
08/2012
1Proteins (Proteins, Gene)IBA
01/2011
1Serotonin (5 Hydroxytryptamine)IBA
08/2010
1Immunoglobulin G (IgG)IBA
08/2010
1Thromboplastin (Tissue Factor)IBA
12/2008
1AnticoagulantsIBA
12/2008
1tranilast (N 5')IBA
01/2007
1bivalirudin (Angiomax)FDA Link
01/2007
1lepirudin (Refludan)FDA Link
01/2007
1CreatinineIBA
12/2006
1Indicators and Reagents (Reagents)IBA
06/2005

Therapy/Procedure

16Amputation
07/2009 - 08/2003
5Renal Dialysis (Hemodialysis)
01/2008 - 12/2004
1Thrombolytic Therapy
12/2008
1Intensive Care (Surgical Intensive Care)
09/2008
1Long-Term Care
10/2006
1Extracorporeal Membrane Oxygenation (ECMO)
01/2006
1Cardiopulmonary Bypass (Heart-Lung Bypass)
01/2006
1Renal Replacement Therapy (Therapies, Renal Replacement)
10/2005